Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700

NCT ID: NCT02333487

Last Updated: 2020-05-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-30
• Study Completion Date: 2016-02-11

Brief Summary

The purpose of this PET study is to verify the binding of Lu AF35700 after multiple oral dosing at the dopamine and the serotonin receptors in male patients with schizophrenia.

Detailed Description

There were 3 to 4 cohorts of 2 patients per receptor group. Lu AF35700 was administered as multiple oral doses for up to 21 days before the PET scans were performed. The doses in all groups were selected with the aim of characterising the exposure response (occupancy) curve. The doses for all groups, with the exception of A1, B1, and C1, were subject to change within the dose range already investigated and found tolerable. The next dose for the groups was established at a dosing conference based on an evaluation of the occupancy obtained, and safety, tolerability, and pharmacokinetic data from all previous cohorts.

Conditions

Schizophrenia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Lu AF35700 (Group D1)

Up to 3 PET scans, besides baseline scan, using \[11C\]-NNC 112 tracer to detect D1 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700

Group Type: EXPERIMENTAL

Lu AF35700

Intervention Type: DRUG

5 mg tablets for oral administration

Lu AF35700 (Group D2)

Up to 3 PET scans, besides baseline scan, using \[11C\]-Raclopride to detect D2 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700

Group Type: EXPERIMENTAL

Lu AF35700

Intervention Type: DRUG

5 mg tablets for oral administration

Lu AF35700 (Group 5-HT6)

Up to 3 PET scans, besides baseline scan, using \[11C\]- Lu AE60157 tracer to detect 5-HT6 (5-hydroxytryptamine-6) receptor occupancy before and after multiple oral dosing of Lu AF35700

Group Type: EXPERIMENTAL

Lu AF35700

Intervention Type: DRUG

5 mg tablets for oral administration

Interventions

Lu AF35700

5 mg tablets for oral administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. The patient is a man aged between ≤18 and ≥60 years

2. BMI of ≥19 kg/m2 to ≤ 37 kg/m2

3. The patient has a primary diagnosis of schizophrenia according to DSM-5™ (code 295.90)

4. The patient has a Clinical Global Impression - Severity of Illness (CGI-S) score ≤ 4 (moderately ill) at screening and safety baseline

5. The patient is currently under oral therapy with one or more of the antipsychotic medications listed in Appendix II.

6. The patient has a Positive and Negative Syndrome Scale (PANSS) total score ≤ 80

7. The patient has a score of ≤ 4 (moderate) on the following PANSS items at screening and at safety baseline: P7 (hostility), G8 (uncooperativeness)

Exclusion Criteria

1. The patient experienced an acute exacerbation requiring hospitalization within the last 3 months.

2. The patient experienced an acute exacerbation requiring change in antipsychotic medication (with reference to drug or dose) within the last 4 weeks.

3. The patient has a diagnosis or history of substance use disorder (except nicotine) according to DSM-5-TR® criteria ≤3 months prior to screening

4. The patient is at significant risk of harming himself or others according to the investigator's judgment or as indicated by an answer of "yes" to the question 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) at the Screening Visit within the last six months on the lifetime version of C-SSRS.

5. Based on investigators judgment the patient has a medical or neurological disorder or treatment for such disorder that could interfere with the study treatment or impair treatment compliance.

6. The patient has had past episodes of extrapyramidal symptoms (EPS) under current medication within the last 3 month

7. The patient takes other medication than those listed as allowed concomitant medication in Appendix III

8. The patient is occupationally exposed to significant levels of ionizing radiation.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

H. Lundbeck A/S

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Email contact via H. Lundbeck

Role: STUDY_DIRECTOR

LundbeckClinicalTrials@lundbeck.com

Locations

US802

Rockville, Maryland, United States

Countries

United States

Other Identifiers

15859A

Identifier Type: -

Identifier Source: org_study_id